A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
This research is testing a medicine called migalastat for people living with Fabry disease. It's specifically for those whose Fabry disease is linked to certain genetic changes that migalastat can help, and who also have significant kidney problems. The study will look at two groups: one with severe kidney damage who are not on dialysis, and another group who are already receiving dialysis treatment. The main goals are to understand how safe migalastat is and how the body processes it in these situations. This is an 'open-label' study, meaning both patients and doctors will know they are receiving migalastat. It's an important step to gather more information about using this treatment in people with advanced kidney disease tied to Fabry disease.
A colpo d'occhio
Di cosa tratta questo studio?
This study is about a medicine called migalastat, used for a rare genetic condition called Fabry disease. Fabry disease can cause lots of health problems, including serious damage to the kidneys. This study is specifically for people with Fabry disease who have certain genetic changes that migalastat is known to work for, and who also have severe kidney problems.
We want to find out more about how safe migalastat is and how the body handles it in people whose kidneys are severely affected. This includes people with very advanced kidney disease who are not yet on dialysis, and also those who are already receiving dialysis treatment. We hope this study will give us valuable information to help doctors best support people with Fabry disease and kidney issues.
It's important to understand that this is an 'open-label' study. This means everyone involved – the patients and the doctors – will know that migalastat is being given. There isn't a comparison group receiving a dummy pill or a different medicine in this particular study.
Punti chiave
- This study is for adults with a specific type of Fabry disease and severe kidney problems.
- It tests a medicine called migalastat to check its safety and how it works in people with kidney damage or on dialysis.
- Participation involves taking migalastat and having regular check-ups.
- You cannot join if you've had a kidney transplant or are on peritoneal dialysis.
- This is an 'open-label' study, so everyone knows you're receiving migalastat.
Chi può essere idoneo?
To join this study, you need to be an adult (18 years or older) with a diagnosis of Fabry disease. Your doctors must have noted that your specific type of Fabry disease, based on your genetic test results, is one that migalastat can help. You also need to have severe kidney problems, meaning your kidney function is quite low, as measured by a specific kidney test within the last three months and again at the start of the study.
If you have very severe kidney disease and are on dialysis, you might still be able to join. However, you would need to be on a regular dialysis schedule (2 or 3 times a week) for at least two months before starting the study. It's also important that you can receive your dialysis sessions at the study clinic or a nearby centre that the study doctor works with, and that you commit to completing all your prescribed dialysis sessions.
Unfortunately, you can't join if you've already had a kidney transplant, or if you're on a different type of dialysis called peritoneal dialysis. You also can't be taking other experimental drugs, or certain specific Fabry disease medications. If you've had certain heart problems recently, or have serious unstable heart or other medical conditions, or a history of allergic reactions to migalastat or similar drugs, you wouldn't be able to take part.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Are you 18 years or older with Fabry disease?
- Has your doctor confirmed your Fabry disease type can be treated with migalastat?
- Do you have severe kidney problems (eGFR below 30)?
- If on dialysis, are you on hemodialysis 2-3 times a week for at least 2 months?
- Have you NOT had a kidney transplant or been on peritoneal dialysis?
- Are you NOT taking other study drugs or certain Fabry medications currently?
Cosa comporta la partecipazione?
If you decide to take part, your first step will be a screening visit to check if you're suitable for the study. This will likely involve confirming your Fabry disease type and your kidney function. If you meet all the requirements, you'll have a main starting visit within a month. During this study, you'll be taking migalastat as prescribed.
For those on dialysis, special arrangements will be made to ensure your dialysis sessions can happen at the study clinic or an affiliated centre, and you'll need to commit to attending all your scheduled dialysis sessions. The study will involve regular check-ups and assessments to monitor your health, how the medicine is working, and to ensure your safety. The total duration of your participation will be explained to you during the consent process.
Rischi e benefici potenziali
Luoghi (12)
- Università di EmoryCodice postale verificatoAtlanta, Stati Uniti
- The Cleveland ClinicCodice postale verificatoCleveland, Stati Uniti
- Lysosomal and Rare Disorders Research and Treatment Center, IncCodice postale verificatoFairfax, United States
- Royal Melbourne HospitalCodice postale verificatoParkville, Australia
- Royal Perth HospitalCodice postale verificatoPerth, Australia
- Osaka University HospitalCodice postale verificatoSuita, Japan
- Shizuoka General HospitalCodice postale verificatoShizuoka, Japan
- Centro Hospitalar e Universitário de Coimbra (CHUC)Codice postale verificatoCoimbra, Portugal
- Hospital Universitari(o) de Bellvitge (HUB) Feixa LlargaCodice postale verificatoBarcellona, Spagna
- Hospital General Universitario de EldaCodice postale verificatoElda, Spain
- Hospital General Universitario Gregorio MarañonCodice postale verificatoMadrid, Spagna
- Ospedale Salford RoyalCodice postale verificatoSalford, United Kingdom
Domande comuni
What is Fabry disease?
Fabry disease is a rare inherited condition that can affect many parts of the body, including the kidneys, heart, and skin, because the body can't break down a certain type of fat properly.
What is migalastat?
Migalastat is a medication used to treat certain types of Fabry disease where the specific genetic change allows the drug to help the body's own enzymes work better.
Why is this study only for people with kidney problems?
This study is specifically looking at how migalastat works and its safety in people with Fabry disease who also have severe kidney damage, including those on dialysis, as there's less information about how the drug behaves in these situations.
Cosa significa 'a etichetta aperta'?
Open-label means that everyone involved in the study – both the patient and the doctors – will know that the patient is receiving the study medication, migalastat.
Dovrò pagare per partecipare allo studio?
No, you will not have to pay for the study medication or any study-related tests and appointments. Travel costs may also be reimbursed.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.